早期乳腺癌超大分割全乳放疗同步整合补量的急性皮肤毒性
2020年3月至2022年3月,383例早期乳腺癌患者纳入前瞻性登记,接受5次、一周内完成的全乳放疗(总剂量26 Gy,5.2 Gy/次),其中272例同步整合补量29 Gy(5.8 Gy/次),111例补量30-31 Gy(6-6.2 Gy/次)。中位随访18个月,全部患者存活且无局部、区域或远处复发,急性耐受性可接受,仅见轻度毒性。作者结论认为该方案可行且耐受良好,但需更长随访确认。
要点
- 5次一周内完成的全乳放疗联合同步整合补量,中位随访18个月全部患者存活且无复发。
- 急性皮肤毒性仅1级182例(48%)、2级15例(4%),无其他急性毒性。
- 中位PTVWBI与皮肤毒性存在统计学显著相关(p=0.028),晚期色素沉着与中位PTVBOOST及PTVBOOST/PTVWBI比值相关(p=0.007和p=0.042)。
核心结论
- 5次一周内完成的超大分割全乳放疗联合同步整合补量可行且耐受良好,但需更长随访确认结果。
研究设计与样本
- 前瞻性登记纳入2020年3月至2022年3月383例早期乳腺癌患者,中位年龄56岁(范围30-99岁),全乳放疗总剂量26 Gy分5次(5.2 Gy/次)。
- 272例(71%)同步整合补量29 Gy分5次(5.8 Gy/次),111例(29%)因切缘近或局灶受累补量30-31 Gy分5次(6-6.2 Gy/次)。
- 放疗技术为三维适形366例(95%)、VMAT 16例(4%)、三维适形联合深吸气屏气4例(1%);93%接受内分泌治疗,43%接受全身或靶向化疗。
- 急性皮肤并发症采用回顾性方式复查。
主要发现
- 中位随访18个月(范围7-31个月),全部患者存活,无局部、区域或远处复发证据。
- 急性皮肤毒性1级182例(48%)、2级15例(4%);乳腺水肿1级9例(2%)、2级2例(0.5%);未观察到其他急性毒性。
- 早期延迟并发症:1级乳腺水肿6例(2%);1级色素沉着20例(5%);补量区下方乳腺硬结1级10例(3%)、2级2例(0.5%)。
- 中位PTVWBI与皮肤毒性发生存在统计学显著相关(p=0.028);晚期色素沉着与中位PTVBOOST(p=0.007)及PTVBOOST/PTVWBI比值(p=0.042)存在统计学显著相关。
局限性
- 原文结论指出需要更长随访来确认这些结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whole-breast irradiation (WBI) after breast conserving surgery (BCS) is indicated to improve loco-regional control and survival. Former studies showed that addition of tumor bed boost in all age groups significantly improved local control although no apparent impact on overall survival but with an increased risk of worse cosmetic outcome. Even though shortened regimens in 3 weeks are considered the standard, recent studies have shown the non-inferiority of a treatment regimen of 5 fractions in one-week in both locoregional control and toxicity profile, although simultaneous integrated boost (SIB) in this setting has been scarcely studied. MATERIALS AND METHODS: From March-2020 to March-2022, 383 patients with early breast cancer diagnosis and a median age of 56 years-old (range 30-99)were included in a prospective registry of ultra-hypofractionated WBI up to a total dose of 26 Gy in 5.2 Gy/fraction with a SIB of 29 Gy in 5.8 Gy/fraction in 272 patients (71%), 30-31 Gy in 6-6.2 Gy/fraction in 111 patients (29%) with close/focally affected margins. Radiation treatment was delivered by conformal 3-D technique in 366 patients (95%), VMAT in 16patients (4%) and conformal 3-D with deep inspiration breath hold (DIBH) in 4patients (1%). Ninety-three per cent of patients received endocrine therapy and 43% systemic or targeted chemotherapy. Development of acute skin complications was retrospectively reviewed. RESULTS: With a median follow-up of 18 months (range 7-31), all patients are alive without evidence of local, regional or distant relapse. Acute tolerance was acceptable, with null o mild toxicity: 182 (48%) and 15 (4%) patients developed skin toxicity grade 1 and 2 respectively; 9 (2%) and 2 (0.5%) patients breast edema grade 1and 2 respectively. No other acute toxicities were observed. We also evaluated development of early delayed complications and observed grade 1 breast edema in 6 patients (2%); grade 1 hyperpigmentation in 20 patients (5%); and grade 1 and 2 breast induration underneath boost region in 10(3%) and 2 patients (0.5%) respectively. We found a statistically significant correlation between the median PTVWBI and presence of skin toxicity (p = 0.028) as well as a significant correlation between late hyperpigmentation with the median PTVBOOST (p = 0.007) and the ratio PTVBOOST/PTVWBI (p = 0.042). CONCLUSION: Ultra-hypofractionated WBI + SIB in 5 fractions over one-week is feasible and well tolerated, although longer follow-up is necessary to confirm these results.
引用
- Montero A, Ciérvide R, Cañadillas C, et al. Acute skin toxicity of ultra-hypofractionated whole breast radiotherapy with simultaneous integrated boost for early breast cancer. Clin Transl Radiat Oncol. 2023. PMID: 37388711. doi:10.1016/j.ctro.2023.100651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。